{
    "eid": "2-s2.0-85119280259",
    "title": "Prevention of Emerging Infections in Children",
    "cover-date": "2022-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pediatrics, Perinatology and Child Health",
            "@code": "2735",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Avian influenza",
        "Chikungunya",
        "Dengue",
        "Ebola",
        "Emerging infections",
        "Middle-East respiratory syndrome",
        "Prevention"
    ],
    "authors": [
        "Thanyawee Puthanakit",
        "Suvaporn Anugulruengkitt",
        "Watsamon Jantarabenjakul"
    ],
    "citedby-count": 1,
    "ref-count": 88,
    "ref-list": [
        "Regional Office for the Western Pacific. Avian Influenza Weekly Update",
        "H5N1 avian influenza in children",
        "Differences in the Epidemiology of Childhood Infections with Avian Influenza A H7N9 and H5N1 Viruses",
        "Probable person-to-person transmission of avian influenza A (H5N1)",
        "Interim Guidance for Infection Control Within Healthcare Settings When Caring for Confirmed Cases, Probable Cases, and Cases Under Investigation for Infection with Novel Influenza A Viruses Associated with Severe Disease",
        "Prevention and Treatment of Avian Influenza A Viruses in People",
        "Interim Guidance on Follow-up of Close Contacts of Persons Infected with Novel Influenza A Viruses Associated with Severe Human Disease and on the Use of Antiviral Medications for Chemoprophylaxis",
        "Clinical vaccine development for H5N1 influenza",
        "Antigen sparing and cross-reactive immunity with an adjuvant rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial",
        "An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults",
        "Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study",
        "AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial",
        "A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59\u00ae: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults",
        "Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial",
        "European Medicines Agency. Foclivia",
        "Adenoviral Vectors as Vaccines for Emerging Avian Influenza Viruses",
        "AS03- and MF59-Adjuvanted Influenza Vaccines in Children",
        "Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015",
        "Middle East respiratory syndrome coronavirus disease in children",
        "Middle East respiratory syndrome coronavirus disease is rare in children: An update from Saudi Arabia",
        "Asymptomatic MERS-CoV Infection in Humans Possibly Linked to Infected Dromedaries Imported from Oman to United Arab Emirates, May 2015",
        "Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Illness in Humans, Saudi Arabia, 2014",
        "Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Aug. 2",
        "Hospital outbreak of Middle East respiratory syndrome coronavirus",
        "Family cluster of Middle East respiratory syndrome coronavirus infections",
        "Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient",
        "Calling for rapid development of a safe and effective MERS vaccine",
        "WHO MERS global summary and Assessment of risk",
        "MERS-CoV as an emerging respiratory illness: A review of prevention methods",
        "Non-genetic factors influencing reproductive traits and calving weight in Saudi camels",
        "Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers",
        "WHO Target Product Profiles for MERS-CoV Vaccines. May 7",
        "Overview of the types/classes of candidate vaccines against MERS-CoV",
        "Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus",
        "Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses",
        "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial",
        "Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial",
        "Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial",
        "Dengue and severe dengue",
        "Dengue guidelines for diagnosis, treatment, prevention and control",
        "The global distribution and burden of dengue",
        "Dengue",
        "Global strategy for dengue prevention and control 2012\u20132020",
        "Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention",
        "Centers for Disease Control and Prevention. Chikungunya",
        "A scoping review of Chikungunya virus infection: epidemiology, clinical characteristics, viral co-circulation complications, and control",
        "Prevention and Control Strategies to Counter Dengue Virus Infection",
        "Paratransgenesis: a promising new strategy for mosquito vector control",
        "Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease",
        "Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy",
        "SAGE Evidence to recommendations framework Table 2",
        "Dengue vaccine: WHO position paper, September 2018 - Recommendations",
        "Ebola, Dengue, Chikungunya, and Zika Infections in Neonates and Infants",
        "Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study",
        "Dengue vaccine development by the year 2020: challenges and prospects",
        "Dengue vaccine: a key for prevention",
        "Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial",
        "An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-1953; an additional note on Chikungunya virus isolations and serum antibodies",
        "Alphaviruses (Chikungunya, Eastern Equine Encephalitis)",
        "World Health Organization. Chikungunya",
        "World Health Organization. Regional Office for South-East Asia. Guidelines for prevention and control of chikungunya fever",
        "Chikungunya",
        "Chikungunya in Children: A Clinical Review",
        "Chikungunya Virus: Clinical Evaluation & Disease",
        "Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies",
        "Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein",
        "Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice",
        "Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553. September 8",
        "A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes",
        "Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial",
        "Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial",
        "Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA",
        "Ebola virus disease",
        "Children's needs in an Ebola virus disease outbreak",
        "Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epid\u00e9mies \u00e0 Kikwit",
        "Ebola haemorrhagic fever",
        "Clinical presentation of patients with Ebola virus disease in Conakry, Guinea",
        "Centers for Disease Control and Prevention. 2014\u20132016 Ebola outbreak in West Africa. March 8, 2019",
        "The evolution of supportive care for Ebola virus disease",
        "Clinical illness and outcomes in patients with Ebola in Sierra Leone",
        "A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics",
        "Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure",
        "Assessment of the risk of Ebola virus transmission from bodily fluids and fomites",
        "Filoviruses and Arenaviruses",
        "Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)",
        "Clinical Surveillance and Evaluation of Suspected Ebola Cases in a Vaccine Trial During an Ebola Epidemic: The Sierra Leone Trial to Introduce a Vaccine Against Ebola",
        "Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report [published correction appears in Lancet Infect Dis. 2017 Dec;17 (12):1232]",
        "Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}